Ironwood Pharmaceuticals - Class A Share Price Today
Ironwood Pharmaceuticals - Class A opened lower at $4.83, compared with its previous close of $4.87. In the last trading session, the stock traded between $4.79 and $5.00. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Ironwood Pharmaceuticals - Class A is now worth
$ 39.42
Resulting in a loss of
$ 60.58 (60.58%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.03 (-0.51%)
Day High
$5.00
Day Low
$4.79
Day Open
$4.83
Prev Close
$4.87
Volume
30,54,040
1W Return
28.17%
1M Return
28.99%
3M Return
12.81%
6M Return
16.19%
1Y Return
67.65%
Fundamentals
Market Cap ($ Mn)
802
PE Ratio
5.35
PB Ratio
-
PEG Ratio
0.00
ROE
-
ROCE
48.87%
EPS (TTM)
$0.36
Investment Returns
1 Week
28.17%
1 Month
28.99%
3 Months
12.81%
6 Months
16.19%
9 Months
9.12%
Financials
Quarterly
All values in $ Mn
85.2
Jun 25
122.1
Sep 25
47.7
Dec 25
106.5
Mar 26
113.0
Jun 26
133.0
Sep 26
Updates
5Nov
Ironwood Pharmaceuticals raises FY26 sales guidance to $485M-$510M
Ironwood Pharmaceuticals raised FY2026 sales guidance to $485 million-$510 million. The new range replaces the previous outlook of $460 million-$485 million. Revised guidance exceeds the analyst estimate of $471.6 million.
7 days ago
5Nov
Ironwood Pharmaceuticals Q3 Results: Adj. EPS $0.36 beats est, sales up 9%
Adjusted EPS of $0.36 beat analyst estimates of $0.32 by 12.5%. Quarterly sales reached $133.04 million, up 9.00% YoY from $122.06 million. Sales exceeded consensus estimates of $121.567 million by 9.44%. Earnings per share rose 50% from $0.24 in the same period last year.
7 days ago
16Oct
Ironwood Pharmaceuticals appoints Tammi Gaskins as CEO effective Jan 2027
Tammi Gaskins appointed CEO effective January 1, 2027. Tom McCourt retires as CEO but remains on Board. Gaskins previously served as Chief Commercial Officer since 2020. Transition aims to advance LINZESS growth and apraglutide trials.
27 days ago
6Aug
Ironwood Pharmaceuticals Inc. Raises FY26 Sales Guidance Above Estimate
Ironwood Pharmaceuticals Inc. upgraded its FY2026 sales guidance to $460.000 million-$485.000 million. The new range surpasses the $460.118 million estimate, reflecting improved revenue expectations.
Ironwood Pharmaceuticals missed Q2 estimates with adjusted EPS of $0.31 versus $0.36 expected and sales of $113.041 million versus $114.844 million expected. However, the company achieved strong year-over-year growth, with EPS up 121.43% and sales up 32.62% compared to the same period last year.
3mo ago
31Jul
Ironwood Pharmaceuticals to host Q2 2026 investor update call
Ironwood Pharmaceuticals scheduled its Q2 2026 investor update for August 6, 2026. The call covers updates on apraglutide and LINZESS. Replays will be available via phone and webcast until August 20, 2026.
